The Immune Paradox: Why the Hormone That Shields Men from Themselves Leaves Them Vulnerable to Everything Else

Every other paradox in this series — bone, cognition, cardiovascular, depression — is downstream of this one. The immune paradox is the original deal. Testosterone suppresses the immune system's tendency to attack its own body while simultaneously weakening its capacity to fight everything else: viruses, bacteria, tumors, vaccines. Evolution accepted this trade-off because autoimmunity was the more immediate threat to reproductive fitness. The modern disease landscape has shifted that calculus. And now, in 2026, we have the first direct human evidence of how the trade-off works — and it's more context-dependent than anyone expected.

The Master Switch

In September 2024, Lakshmikanth and colleagues at the Karolinska Institute published the most important study on testosterone and immunity ever conducted. They followed 23 transgender men receiving testosterone therapy over 12 months, with serial blood draws and deep immunophenotyping — 46 immune cell populations, 253 plasma proteins. It was the first longitudinal, within-subject human experiment isolating testosterone's effects on the immune system.

What they found was not a simple suppression. It was a switch.

This is the skeleton key. Type I interferons are the body's first alarm system against viruses. TNF pathways coordinate inflammatory defense against bacteria and tissue repair. Testosterone tilts the balance toward the latter at the expense of the former. This single axis explains why men are more susceptible to viral infections (COVID, influenza) but less susceptible to the autoimmune conditions driven by overactive IFN-I signaling.

The Shield Against the Self

Women develop autoimmune diseases at 4-10× the rate of men, depending on the condition. This isn't a statistical curiosity — it's the most dramatic sex difference in medicine. The protection testosterone provides operates through at least five distinct mechanisms, each independently validated.

1. The BAFF brake

B-cell activating factor (BAFF) is the survival signal for autoreactive B cells — the cells that produce antibodies against the body's own tissues. Wilhelmson and colleagues (Nature Communications, 2018) showed that testosterone directly suppresses BAFF production by fibroblastic reticular cells in the spleen. Remove testosterone, and BAFF-producing cells expand. B cell populations grow. Autoantibody production rises. Among healthy men, those with lower testosterone have measurably higher serum BAFF.

This matters because belimumab — the anti-BAFF antibody approved for lupus — works by doing pharmacologically what testosterone does naturally. Evolution designed the brake; medicine had to reinvent it.

2. The Th1/Th17 → Treg shift

In April 2025, a study in JCI Insight confirmed that testosterone directly suppresses differentiation of Th1 and Th17 cells — the CD4+ subtypes that drive tissue-destructive autoimmunity — while promoting regulatory T cells (Tregs) that maintain self-tolerance. AR-deficient T cells showed increased IL-17A, IL-22, and IFN-γ production. The earlier mechanistic basis came from Kissick (PNAS, 2014): testosterone upregulates PTPN1, which inhibits IL-12/Stat4 signaling, blocking the Th1 differentiation cascade.

3. The mast cell pathway (MS-specific)

Brown and colleagues (PNAS, 2018) identified a testosterone-dependent pathway specific to multiple sclerosis protection. Testosterone primes mast cells to produce IL-33, which activates type 2 innate lymphoid cells (ILC2s), which drive a protective Th2 response that suppresses pathogenic Th17 cells. Male mast cells are epigenetically primed to produce more IL-33 through long-term androgen exposure — a sex difference that persists even after castration in animal models. This explains why MS is 3-4× more common in women, and why up to 40% of men with MS have low testosterone.

The UCLA pilot (Sicotte, JAMA Neurology, 2007, n=10) gave testosterone to men with relapsing-remitting MS: 67% reduction in brain atrophy rate, cognitive improvement, increased BDNF. A French Phase 2 RCT (TOTEM, NCT03910738) in hypogonadal men with RRMS on natalizumab remains without published results as of March 2026.

4. The synovial aromatase cycle (RA-specific)

In rheumatoid arthritis, the joint itself becomes an androgen sink. Proinflammatory cytokines (TNF-α, IL-1β) upregulate aromatase activity in synovial tissue, converting local androgens to estrogens — specifically 16α-hydroxylated metabolites that are proproliferative and proinflammatory. As local androgen levels fall, aromatase activity increases further, creating a self-reinforcing vicious cycle. Castagnetta (2003) found the RA synovial fluid estrogen/androgen ratio was 1.17 versus 0.29 in controls — a complete inversion. DHEA conversion yielded 708 pmol/L estradiol but only 88 pmol/L testosterone.

This tissue-level effect means systemic testosterone measurement misses the local depletion entirely. A man's blood test can be normal while his joints are androgen-depleted. Panevin et al. (2024) found 24.1% testosterone deficiency in 170 men with RA — associated with metabolic comorbidity, not RA activity itself. Anti-TNF therapy appears to block the androgen-to-estrogen conversion, which may partly explain why men respond differently to biologics.

5. The thymic quality filter

Testosterone accelerates thymic involution — shrinking the organ that trains new T cells. This reduces the supply of naïve T cells, which weakens adaptive immunity against new pathogens. But testosterone simultaneously promotes Aire expression in thymic epithelial cells. Aire controls negative selection: the process of eliminating T cells that would attack the body's own tissues. More Aire = better self-tolerance = less autoimmunity. ADT patients who regain naïve T cells through thymic rejuvenation also gain autoimmune risk — fewer cells, but better cells, is the androgen strategy.

The cohort evidence

These five mechanisms converge in population data. A study of 123,460 men in Clinical Rheumatology found untreated hypogonadism predicted autoimmune disease development:

Klinefelter syndrome (47,XXY) amplifies the signal through a dual mechanism: extra X chromosome dosage — immune-regulatory genes escaping X-inactivation, perturbing Jak-STAT signaling, doubling TLR7 expression — combined with testosterone deficiency. English national linkage data shows the scale of this effect:

TRT in KS reduces IgA, IgG, IgM, IL-2, and IL-4 — direct immunosuppressive effect in humans. Whether this prevents autoimmune disease development remains untested in any longitudinal trial.

The Cost of the Shield

Every layer of autoimmune protection has an infection-side cost. The IFN-I suppression that prevents autoimmunity also disables the first-line antiviral alarm. The Th17 dampening that prevents tissue destruction also weakens mucosal defense. The thymic pruning that eliminates self-reactive cells also reduces the naïve T cell repertoire. COVID-19 made this trade-off visible at population scale.

COVID as natural experiment

Men had 1.7× the case fatality rate of women from COVID-19. This fact alone seemed to indict testosterone as dangerous. But the data tell a more complicated story.

A 2024 meta-analysis in Scientific Reports (18 series, 1,575 patients) quantified the relationship between testosterone and COVID severity:

Hospitalized men's testosterone dropped to 2.5 nmol/L on average — versus 10.4 in controls. 89.8% were hypogonadal on admission. The critical distinction: testosterone's immunosuppressive effects increased initial susceptibility to infection, but once infected, the loss of testosterone's anti-inflammatory brake unleashed the cytokine storm that killed. The net effect of adequate testosterone in COVID was protective.

This was confirmed by the failure of every anti-androgen COVID trial. If testosterone were driving severity, blocking it should help. It didn't. Pre-existing hypogonadism was a risk factor for hospitalization. And a 2024 review in Clinical Endocrinology (Groti Antonič) consolidated the evidence: testosterone levels during acute COVID were inversely proportional to inflammatory cytokines and disease severity.

The sepsis inversion

A 2026 Mendelian randomization study in Critical Care produced a finding that inverts the cardiovascular MR signal entirely. Genetically predicted higher testosterone was associated with improved survival in septic shock. In my cardiovascular paradox article, I reported that genetically higher testosterone predicts higher CAD risk. In sepsis, the same genetic instrument predicts the opposite — better outcomes.

The reconciliation: in health, lifetime high testosterone means lifetime immunosuppression and higher blood pressure — net negative for atherosclerosis. In critical illness, higher genetic testosterone means more hormonal reserve before depletion — net positive for surviving the inflammatory collapse. Context determines whether the same biology helps or harms.

Vaccines: the expected cost

If testosterone suppresses type I interferon signaling, it should dampen vaccine responses. Furman and colleagues (PNAS, 2014) at Stanford found exactly this: men with the highest testosterone had the lowest influenza antibody responses, mediated through a lipid metabolism gene cluster. But the evidence is messier than this single study suggests — some COVID vaccine studies show a positive testosterone-antibody correlation, and hepatitis B data is similarly mixed. The picture may depend on which arm of the immune system the vaccine engages: vaccines that require strong IFN-I responses may be dampened by testosterone; those that work through TNF/antibacterial pathways may not be.

The Cancer Immunosurveillance Paradox

Inside the immune paradox lives a smaller paradox that resists easy resolution. The molecular evidence says testosterone should make cancer worse. The clinical evidence says the opposite.

The molecular case against testosterone

Kwon et al. (Science Immunology, 2022) showed that androgens promote CD8+ T cell exhaustion — the state where killer T cells lose their ability to attack tumors. The mechanism is direct: androgen receptor activation drives Tcf7/TCF1-dependent transcriptional programs that push CD8+ cells toward progenitor exhaustion. Male mice showed more progenitor exhausted CD8+ T cells than females in tumor models, and the effect was gonadal — not chromosomal.

Guan et al. (Nature, 2022) confirmed that AR blockade prevented T cell exhaustion and improved anti-PD-1 responses. AR binds directly to the Ifng locus. In March 2025, Chesner (Cancer Discovery) identified a third mechanism: AR represses MHC class I antigen presentation through a genome-wide CRISPRi screen — making tumors less visible to the immune system.

Three independent mechanisms, all pointing the same direction: testosterone should worsen cancer outcomes.

The clinical reality

It doesn't. Two major meta-analyses — Conforti (Lancet Oncology, 2018, n=11,351) and a 2024 MDPI analysis (n=63,755) — show that men derive greater benefit from immune checkpoint inhibitors than women (HR 0.77 vs 0.81, P=0.0019). An AACR 2023 analysis found 92% anti-PD-1 response rate in the presence of testosterone versus 58% in females. Castration reduced response rates to 71%. Testosterone supplementation in females raised response rates to 85%.

The disconnect between preclinical promise and clinical failure extends to combination trials. Phase 3 trials combining AR suppression with checkpoint inhibitors (IMbassador 250, KEYNOTE-921) both failed. A December 2025 review in Trends in Immunology confirmed that AR inhibition enhances T cell function across multiple cancer types preclinically — but noted the consistent clinical failure without explanation.

Three candidate resolutions

The disconnect likely reflects multiple overlapping mechanisms:

The cancer immunosurveillance paradox may ultimately not be a paradox at all but a sampling artifact: the same immune suppression that lets tumors grow also makes them more sensitive to the drugs that unleash immunity. The tumors that form under testosterone's cover are naive to immune attack — and therefore most vulnerable when immune attack is therapeutically restored.

The Cell-Type Matrix

The reason the immune paradox resists single-sentence summaries is that testosterone does different things to different cells. The same hormone, binding the same receptor, produces opposite outcomes depending on cell type and tissue context.

Sources: Ainslie, J Endocrinol 2024; Lakshmikanth, Nature 2024; Kissick, PNAS 2014; JCI Insight 2025; Wilhelmson, NatComms 2018; Kwon, Sci Immunol 2022; Brown, PNAS 2018; Chesner, Cancer Discov 2025.

The matrix reveals the architecture of the bargain. The left column — Th1/Th17 suppression, Treg promotion, BAFF reduction, mast cell IL-33 — is a coordinated anti-autoimmune program. The right column — IFN-I suppression, CD8+ exhaustion, reduced antigen presentation — is the price. But two cell types — macrophages and NK cells — refuse to be categorized, producing opposite effects depending on tissue context. These are the cells that make simple "immunosuppressive" labeling inadequate.

The Double Jeopardy

The clinical consequence of the immune paradox for hypogonadal men is worse than either side alone. Losing testosterone means losing the autoimmune shield and losing the anti-inflammatory brake that prevents fatal overreaction during infection. It is double jeopardy:

The sepsis MR finding crystallizes this: genetically higher testosterone predicts better survival in septic shock because it represents more hormonal reserve before depletion. Men who start with less have less to lose — and they lose it fastest.

What Doesn't Exist

The monitoring void around testosterone and immunity is total. No screening guideline recommends checking autoimmune markers in hypogonadal men, despite HR 1.33 for autoimmune disease. No guideline recommends checking testosterone in men presenting with autoimmune conditions, despite 24.1% deficiency in RA and 13.2% in SLE. No infectious disease guideline accounts for hypogonadal status in risk stratification, despite COVID showing that testosterone levels predict survival.

Specific voids:

• Zero RCTs of TRT for autoimmune disease prevention in hypogonadal men. The KS data shows TRT reduces immunoglobulins and cytokines — but no one has tested whether this prevents autoimmune disease onset.
• Zero large studies of immune function in men receiving TRT for hypogonadism. Existing data comes from trans men (Lakshmikanth) or small RA pilots. The immunological profile of the 11 million men on TRT prescriptions annually is unmapped.
• The TOTEM trial (testosterone in MS) — the only RCT testing testosterone's autoimmune-protective mechanism in a specific disease — has no published results after enrollment completion. The UCLA pilot was 2007. It has been 19 years.
• Zero vaccine dosing adjustments account for testosterone status, despite Stanford data showing testosterone determines influenza antibody response magnitude.
• Zero treatment modality comparisons for immune effects. TRT suppresses gonadotropins; SERMs and hCG raise them. Whether gonadotropins themselves affect immune function — as they affect neurodegeneration — is unstudied.

The immune paradox is the deepest in this series because it is the oldest. Every cell in the male body lives with this bargain — protection against the self at the cost of defense against the world. The modern clinical failure is that no one monitors either side of it. Men with hypogonadism are screened for bone density, cardiovascular risk, metabolic syndrome, and mood. No one checks their BAFF levels, their Th17/Treg balance, their IFN-I response capacity, or their vaccination adequacy. The shield and its cost are both invisible.